Functional Maturation of Drug Transporters in the Developing, Neonatal and Postnatal Kidney


Division of Nephrology & Hypertension, Departments of Medicine (D.E.S., V.V., T.R., W.W., S.K.N.), Pharmacology (V.V.), Pediatrics (T.F.G., S.K.N.), and Cellular and Molecular Medicine (S.K.N.), University of California, San Diego, La Jolla, CA 92093, and the Department of Medicine, San Diego VA Healthcare System, La Jolla, CA 92161 (V.V., T.R.).
RUNNING TITLE  Maturation of drug transporters

CORRESPONDANCE TO  Sanjay K. Nigam, Department of Medicine, University of California San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093; Tel. (858) 822-3482; Fax. (858) 822-3483; E-mail: snigam@ucsd.edu

No. of text pages: 31
No. of tables: 4 (Supplementary Tables 1-4)
No. of figures: 6 figures
No. of references: 40
No. of words in the Abstract: 250
No. of words in the Introduction: 552
No. of words in the Discussion: 1106

ABBREVIATIONS: OAT, organic anion transporter; PAH, para-aminodipururate; ABC, ATP-binding cassette; SLC, solute carrier; NSAIDs, non-steroidal anti-inflammatory drugs; GUDMAP, genitourinary development molecular anatomy project; early emb, early embryonic; intern emb, intermediate embryonic; late emb, late embryonic; UT, ureteric tip; PT, proximal tubules; RC, renal corpuscle; MM, metanephric mesenchyme; CM, cap mesenchyme; RV, renal vesicle; SS, s-shaped body; AH, Loop of Henle; UB, ureteric bud; CCD, cortical collecting duct; MC, medullary collecting duct; UR, urothelium; US ureteral smooth muscle; MI, medullary interstitium; CI, cortical interstitium; e, embryonic day; w1, week 1; w4, week 4; ad, adult.
ABSTRACT

Since renal function in newborns is immature, the pharmacokinetics of drugs administered to neonates vary significantly from adult patients. The establishment of drug transport systems is a key process in the functional maturation of the nephron. However, a thorough examination of the expression of the main drug transporters in the kidney throughout all stages of development (embryonic, postnatal and mature) has yet to be carried out and the functional (physiological) impact is not well understood. Using time-series microarray data, we analyzed the temporal behavior of mRNA levels for a wide range of transporters in the rodent kidney throughout a developmental time series. We find dynamic increases between the postnatal and mature stages of development for a number of transporters, including the proximal tubule-specific drug and organic anion transporters (OATs) OAT1 and OAT3. The OATs are the major multispecific basolateral drug, toxin and metabolite transporters in the proximal tubule responsible for handling of many drugs, as well as the prototypical OAT substrate p-aminohippurate (PAH). We therefore performed specific in vivo pharmacokinetic analysis of the transport of PAH in postnatal and maturing rodent kidney. We show that there is a 4 fold increase in PAH clearance during this period. Clearance studies in Oat1 and Oat3 knockouts confirm that, as in the adult, Oat1 is the principle transporter of PAH in the postnatal kidney. The substantial differences observed supports the need for better understanding of pharmacokinetics in the newborn and juvenile kidney compared to the adult kidney at the basic and clinical level.
INTRODUCTION

At birth the fetus transitions from an aqueous environment in utero to a terrestrial environment. The physiological changes that are initiated at birth affect all organ systems to accommodate the rapidly shifting environment. A key issue has to do with developmental changes in drug and toxin transporters in the kidney and other organs that function at epithelial interfaces between the newborn and the outside world. Transporters involved in the maintenance of homeostatic balance within this new environment must be adequately expressed and functionally regulated so that rapid environmental shifts and changes can be accommodated or recovered from safely (Wu et al., 2011).

The kidneys play a particularly critical role in the elimination of toxins and drugs which may be encountered by or administered to the newborn. For example, various transporters including the ABC (ATP-binding cassette) and SLC (Solute carrier) families of transporters, together, are responsible for the transport of a majority of the drugs handled by the kidney. In particular, the transporters of SLC22 subfamily mediate the secretion of both endogenous and exogenous organic anions including a number of xenobiotics and pharmacological drugs. Endogenous and exogenous organic anions, including β-lactam antibiotics, HIV antiviral drugs, and diuretics, are excreted from the kidney by glomerular filtration as well as by secretion across the proximal tubule via these transporters (Miyazaki et al., 2004; Nigam et al., 2007). The gene products of both Slc22a6 (OAT1) and Slc22a8 (OAT3) are localized to the basolateral membrane of
the proximal tubule (Kojima et al., 2002) and contribute to the secretion of a number of therapeutic agents and endogenous organic anions (Burckhardt and Burckhardt, 2003; Eraly et al., 2006; Vallon et al., 2008).

It is known that the newborn kidney has a lower glomerular filtration rate compared to the adult and that the concentration of urine and secretion of organic compounds is reduced (Hook and Bailie, 1979), and that renal expression of Oats increases substantially in postnatal rats and mice (Buist et al., 2002; Buist and Klaassen, 2004). Neonatal pharmacokinetics differ from adult parameters due to this functional renal immaturity, and it cannot be assumed that drug treatment of a newborn or premature infant can be extrapolated from the kinetics or therapeutic efficacy observed in adult patients (Warner, 1986). In addition, the immature nature of the drug transport system at birth not only makes the kidney itself prone to toxic injury (Sekine and Endou, 2009), but also leaves other organ systems vulnerable to toxicants when the pharmacological agent has lower clearance rates. Although toxic injury due to the misdosing of drugs is a concern regardless of age, based on the immaturity of drug transport mechanisms, newborns can be particularly susceptible to overdosing from prescription errors (Chappell and Newman, 2004).

In light of this, pharmacokinetic and dynamic studies specifically targeting the newborn are of critical importance for effective therapeutic treatment of this vulnerable population. However, little is known about the temporal expression of the main drug
transporters throughout kidney development into adulthood. Using microarray analysis we carried out a comprehensive analysis of the profile of expression of SLC, ABC and SLC22 transporter families in the rodent kidney from early embryonic timepoints, through newborn stages and into maturity. Given the importance of OAT1 and OAT3 function in the elimination of a number of clinically important drugs we also performed a pharmacokinetic analysis using the prototypic substrate p-aminohippurate (PAH) during the neonatal period to gain insight into the functional state and maturation of the renal drug transport system.
MATERIALS AND METHODS

Microarray Analysis. Microarray analysis was carried out using Genespring GX 11 software. The whole embryonic rat kidney time course data was obtained from previously published datasets (Tsigelny et al., 2008), and the mouse datasets from GUDMAP were downloaded at www.gudmap.org. All microarray datasets were processed using RMA (robust multi-array analysis) normalization. The average expression for each timepoint in each stage was calculated. SLC, ABC and SLC22 gene lists were compiled based on the probe set annotations on the Affymetrix rat 230 2.0 chip. The translate function in Genespring GX11 was used to translate probe set IDs between the Affymetrix rat 230 2.0 chip and the mouse 430 2.0 chip. Homology was based on Entrez gene ID annotations. For each graph of gene expression the y-axis represents normalized intensity of expression in log₂ scale. Full lists and expression data corresponding to all gene expression profiles (Figures 1A, 1B, 2A, 2C, 3A, and 4A) are provided in Supplementary Tables 1-4.

Oat1 and Oat3 knockout mice (Oat1⁻/⁻, Oat3⁻/⁻). Oat1⁻/⁻ mice (Eraly et al., 2006) and Oat3⁻/⁻ mice (Sweet et al., 2002) were back-crossed to C57BL/6J mice for 10 generations. Heterozygous mice from the final back-cross were bred to each other to generate knockout (⁻/-) and wild-type (WT) mice, from which all the animals used in the experiments described were descended. Female and male mice, at 1, 2, 3 and 8 weeks of age, were used in the present experiments. Mice were genotyped by PCR. All
experimental protocols were in accordance with the *Guide for Care and Use of Laboratory Animals* (National Institutes of Health, Bethesda, MD) and were approved by the Institutional Animal Care and Use Committee.

**PAH clearance experiments in wild-type mice at 1, 2 and 3 weeks of age.** During brief isoflurane anesthesia, PAH solution (77 µmol/kg; including cold and $^{14}$C-labelled PAH in 0.85%NaCl) was injected into the retro-orbital plexus (2 µl/g/body weight). At 3, 7, 10, 20, or 40 min after injection (3, 7, 10, 20, or 40 min in 2 week old mice; 5, 10, 15, 20 min in 1 and 3 week old mice), trunk blood was collected in heparinized capillaries after euthanization. After centrifugation, 10 µl of plasma was analyzed for PAH by scintillation counting. PAH volume of distribution, elimination constant, and clearance were calculated using a two-compartment model of two-phase exponential decay (GraphPad Prism, San Diego, CA) (Vallon et al., 2009), using data from 5 animals to generate one decay curve.

**2 Week postnatal Inulin and PAH clearance in Oat1<sup>−/−</sup>, Oat3<sup>−/−</sup> and wild-type.** Studies were performed as described above with addition of $^{3}$H-inulin (20 µg/kg) to the injection solution to also determine inulin clearance as previously described (Vallon et al., 2009).

**Statistical analysis.** Data are shown as means ± SEM. Unpaired Student’s t-test was performed to analyze for statistical differences between knockout and WT mice with $P<0.05$ being considered to be statistically significant.
RESULTS

Expression of SLC and ABC transporters in the embryonic, neonatal and mature kidney

The SLC and ABC transporter families comprise the two large families of drug transporters in the genome (He et al., 2009; Vasiliev et al., 2009; Wu et al., 2009). We sought to determine the expression profile of a comprehensive set of these transporters utilizing microarray expression data from rodent (rat) kidneys. Previously published data profiling the whole kidney transcriptome from its initial formation at e13 through each consecutive day of embryonic development (e14-e22) as well as time points profiling the kidney at birth (P0), week 1, week 4 and adulthood was obtained (Tsigelny et al., 2008). A stage model as described in Tsigelny et al. was employed to focus on the main transitional changes in gene expression across the dataset (Tsigelny et al., 2008). In brief, this stage model was computed based on the similarity of gene expression of the timepoints from cluster analysis. The resultant five stages of kidney development were as follows: the early embryonic stage of kidney development consisted of e13, e14, e15 and e16 timepoints; the intermediate embryonic stage consisted of e17 and e18; the late embryonic stage was inclusive of e19, e20, e21 and e22; the postnatal stage consisted of P0 and week 1; and the mature stage was a grouping of week 4 and adult kidney. Using this stage model of gene expression of the whole embryonic kidney, SLC and ABC transporter genes were examined (Figure 1). In general there is an upward trend in expression for the SLC (Figure 1A; Supplemental
Table 1)) and ABC (Figure 1B; Supplemental Table 2) transporters, with a number of the transporters showing maximal expression at the mature stage.

Analyzing the expression of SLC22 family of transporters in the embryonic, neonatal and mature kidney

Next we examined the expression of the SLC22 family of transporters. This family of transporters is responsible for the transport of organic cationic as well as anionic (and zwitterionic) molecules across the cell membrane and so has relevance as potential transporters of drug substances of similar chemical nature. Although there is some data on embryonic expression (Pavlova et al., 2000; Sweet et al., 2006), detailed time-series analysis of the subfamily has not been done. Of the 17 probe sets for the SLC22 genes examined (profile plot as in Figure 2A; Supplemental Table 3), 12 showed a 2 fold change or greater between two temporally consecutive stages of kidney development (Figure 2B). Comparison of consecutive stages (according to (Tsigelny et al., 2008)) were performed between the early embryonic and the intermediate embryonic stages, the intermediate embryonic and late embryonic stages, the late embryonic and postnatal stage and finally between the postnatal stage and mature stage. Notably, in almost all cases (except for Oat3 and Octn2), the largest fold-change in expression occurred between the postnatal and mature stage of kidney development. Specific expression of the drug transporters Oat1 (Slc22a6) and Oat3 (Slc22a8) were also examined across the individual timepoints from embryonic day 13 to e22, newborn,
week 1, week 4 and adult to further highlight the progressive increase in mRNA expression levels over the entire developmental timecourse (Figure 2C).

**Investigating clinically important drug transporters in the developing kidney and developing nephron segments**

Our findings indicate that there is a general tendency for members of the SLC, ABC and SLC22 families of transporters to have naturally increased expression as renal development of the kidney proceeds and that the largest increase in expression is often observed between the postnatal and mature stage of kidney development. However, it is unclear which subsets of these transporters have specific and potentially therapeutic roles in drug secretion and/or retention in the kidney. A recent review published by the International Transporter Consortium outlined a select list of SLC and ABC transporters which have emerging clinical relevance for the absorption and disposition of drugs across epithelial interfaces (Giacomini et al., 2010). Accordingly, we determined the expression profiles of these clinically important transporters during kidney development (Figure 3A; Supplemental Table 4). Of the 22 probe sets examined for these transporters, 11 showed a 2-fold increase in at least one consecutive stage comparison (Figure 3B). By comparing the expression profiles between temporally sequential stages, it is evident that for the majority of these transporters the greatest fold change in expression occurs between the transition between birth to maturity (the comparison between the postnatal stage and the mature stage).
Although it is clear that the largest increase in “pharmacologically” relevant transporters also seems to occur between birth to maturity in the kidney, it was also important to determine whether the localization of these transporters was specific to a developing nephron segment of the embryonic kidney. The embryonic kidney comprises a number of developing nephron and collecting duct segments such as the ureteric bud, proximal tubules and renal corpuscles (Figure 4A) each of which have individual transcriptomic expression profiles as differentiation proceeds. To facilitate the examination of the localization of the transcripts for transporters in these developing nephron segments, the GUDMAP consortium microarray datasets were utilized (Brunskill et al., 2008). Microarray datasets were obtained for a number of developing mouse nephron segments including the e11.5 metanephric mesenchyme (MM), e15.5 cap mesenchyme (CM), e12.5 renal vesicle (RV), e15.5 S-shaped body (SS), endothelial cells, podocytes, e15.5 renal corpuscle (RC), e15.5 proximal tubules (PT), e15.5 anlage of and immature loop of Henle (AH), e11.5 ureteric bud (UB), e15.5 ureteric tip region (UT), e15.5 cortical collecting duct (CC), e15.5 medullary collecting duct (MC), e15.5 urothelium (UR), e15.5 ureteral smooth muscle layer (US), e15.5 medullary interstitium (MI), e15.5 cortical and nephrogenic interstitium (CI). We applied two-fold filtering in pairwise comparisons between each of these nephron components on the list of clinically important drug transporters. There was a propensity for high expression of a number of transporters in the developing proximal tubule (Figure 4A). Specifically six of the drug transporters show significant upregulation in the developing proximal tubule over all other structures (Figure 4B) including the basolateral transporters Oat1 and Oat3. This
implies that the drug transport function may be partially established even in the e15.5 proximal tubule and that drug transporters already show distinct segmental localization along the nephron even at this relatively early time point during kidney development. These transporters may be functional even at this time (Rosines et al., 2007; Sweet et al., 2006).

Investigating the functional maturation of OAT1 and OAT3 in the postnatal kidney using PAH as a representative organic anion for in vivo physiological studies.

Both Oat1 and Oat3 are upregulated in the maturing kidney and are specifically upregulated in the developing proximal tubule. These transporters mediate the basolateral uptake of a plethora of drugs including NSAIDS, antivirals, beta-lactams and methotrexate (Miyazaki et al., 2004; Nagle et al.; Nigam et al., 2007; Sekine et al., 2000; VanWert et al., 2007). Our previous studies in adult knockout mice for these two genes revealed that OAT1 but not OAT3 mediates the proximal tubular secretion of the prototypic organic anion p-aminohippurate and endogenous organic anions (Eraly et al., 2006; Vallon et al., 2008). OAT1 and OAT3 are also essential for diuretic delivery into the lumen of the proximal tubule (Vallon et al., 2008). Whereas some information is available on the OAT1 and OAT3 systems in adult rats, mice, and humans, very little is known about the newborn and juvenile situation, yet many of these drugs are also applied in the neonatal period.
Since the increased expression of transporters of the rodent kidney from 1-3 weeks may reflect the functional maturation of the human kidney during the first year of life (Holtback and Aperia, 2003) we sought to determine the functional state of the OAT transporters in the postnatal rat kidney. Using PAH as a representative organic anion, PAH clearance experiments were carried out in wild-type mice at 1, 2 and 3 weeks of age (2-3 sets of female and 2-3 sets of male mice per time point). Whereas the volume of distribution for PAH was not different for WT mice at 1, 2 or 3 weeks of age, there was an age-dependent increase in the elimination constant and in the clearance of PAH (Figure 5A and B). Including data from previous analyses of PAH clearance in adult WT mice (8-10 weeks) (Eraly et al., 2006; Vallon et al., 2008) revealed a further increase in PAH clearance between 3 and 8-10 weeks of age (Figure 5C). This suggests that, although organic anion transport is functional in the postnatal pups, its activity is immature and is dependent on the age of the neonate. The data seems generally consistent with the expression profiling described earlier.

The *in vivo* clearance of PAH by OAT1 and OAT3 in the postnatal kidney

Studies in knockout mice revealed that Oat1 is the principle transporter of PAH in the adult (Eraly et al., 2006; Vallon et al., 2008). However it is unclear whether this is the case in the newborn, which is in a dynamic state, at least based on the expression data presented here. This is an important issue since newborns and juveniles may be dosed with organic anion drugs based upon extrapolations from adult studies. To investigate this further we carried out inulin and PAH clearance in Oat1−/−, Oat3−/− and wild-type mice.
at 2 weeks of age (Figure 6). Body weight and the volume of distribution for PAH and inulin were similar between WT and Oat1\(^{-/-}\) and Oat3\(^{-/-}\) mice (Figure 6A and 6B). Whereas the clearance of inulin was comparable between genotypes, the clearance of PAH and the difference between PAH and inulin clearance (as an indirect measure of renal PAH secretion) were significantly lower in Oat1\(^{-/-}\) than in WT mice (Figure 6B and C). Figure 6B presents the combined data for male and female mice since parameters were not significantly different between gender (e.g., PAH clearance and PAH secretion in WT female vs male were 16±1 vs 17±1 µl/min/g and 7±2 vs 5±1 µl/min/g (n=3/gender; NS)). Similarly, PAH clearance and PAH secretion were not different between Oat3\(^{-/-}\) female vs male (14±2 vs 14±1 and 4±1 vs 4±1 µl/min/g; n=3-4/gender; NS) or Oat1\(^{-/-}\) female vs male (10±1 vs 12±2 and 2±1 vs 2±1 µl/min/g; n=3/gender; NS). The PAH clearance tended to be lower in Oat3\(^{-/-}\) mice but this did not reach statistical significance. This suggests that OAT1 mediates the proximal tubular secretion of PAH in the postnatal kidney.
DISCUSSION

The kidney is comprised of a number of epithelial cell types which carry out various essential roles including metabolite excretion, electrolyte homeostatic maintenance and drug and toxin transport. Although pharmacokinetic studies often focus on the fate of drugs in the adult situation, there is a critical need to understand the kinetics of pharmacological agents in newborns and infants given that their renal functional capacity is still undergoing maturation (Hook and Bailie, 1979). Using previously published rat and mouse mRNA microarray expression data we describe the expression of many components of the major drug transport systems during kidney development, through the postnatal period and on to adulthood. Overall, there appears to be an upregulation of the SLC and ABC transporters with developmental time. The expression of SLC22 family of transporters also increases with time, but perhaps of particular interest are the clinically relevant transporters, of which 11 transporters are upregulated at least 2-fold across the development stages analyzed.

The specific expression of a large proportion of these clinically relevant transporters (Slc47a1, Slc22a2, Slc15a2, Slc22a1, Slc22a6 and Slc22a8) in the e15.5 developing proximal tubule suggests that drug transport systems are present early in renal development. In fact, it has been shown previously using whole embryonic kidney culture in vitro that OAT1 mediated uptake of the fluorescent specific substrate
fluorescein can be observed after a week of culture of an e13 rat kidney, a time at which proximal tubule formation should be well underway (Sweet et al., 2006).

The expression of Oats in postnatal development has been measured in mice and rats previously (Buist et al., 2002; Buist and Klaassen, 2004) and shown to increase to mature levels in the weeks following birth. Oat1 and Oat3 proteins localize to proximal tubule (Hwang et al., 2010), and increases in staining are visible until three weeks postnatally, when the tissue is similar in protein level to the adult organ but remains early enough in development that gender based differences are negligible. Although there exist some differences in the expression and or localization of Oat drug transporters along the nephron in different species (Enomoto et al., 2002; Kojima et al., 2002; Ljubojevic et al., 2004; Wu et al., 2009), rodents provide an accessible model to carry out pharmacodynamic and kinetic studies. In light of these divergences, experimental studies using human tissues and cells would be ideally relevant for clinical benefit. However the study of the subtle differences between rodent and human may be key to understanding the vulnerabilities and susceptibilities to drug/metabolite toxicity that have evolved in humans. While previous analyses of expression and protein localization corroborate a dramatic increase in expression, there has yet to be a functional analysis of the transport systems to examine the crucial postnatal developmental phase.

The maturation of the organic anion transport systems in the postnatal mouse kidney was studied using the prototypic organic anion PAH. The kinetics of PAH reflect the
kinetic behavior of any pharmacological agent transported by OAT1. Clearance of PAH increases nearly 4-fold between week 1 and week 3 in the mouse and, by using data from mature mice, it is clear that this increase continues from 3 weeks to adulthood. Therefore, the drug transport system can be considered relatively immature even at 3 weeks of age in the mouse. The attenuation of PAH clearance in the Oat1 knockout animal confirms that PAH is indeed transported via OAT1 in the young kidney similar to the adult situation.

Although there were increases in both mRNA levels of clinical drug transporters and in PAH clearance in the kidney in the postnatal to mature period, it is still unclear what triggers these increases. Previous studies suggest that hormonal regulation may be responsible for the expression of the transporters. Studies have shown that gender differences in Oat1 expression are influenced by the sex steroids testosterone and estradiol (Ljubojevic et al., 2004). It is also known that the corticosteroid dexamethasone, increases PAH uptake in both rat and human renal slices (Fleck et al., 2002). Thyroid hormones have also been implicated in the regulation of OAT activity in the postnatal kidney, using assessment of PAH clearance (Braunlich, 1984). Given that there is a surge in the levels of catecholamine, glucocorticoids and thyroid hormones at birth (Blackburn, 2007; Challis et al., 2000; Freemark, 1999), it is possible that circulating hormone levels are responsible for the maturational increases in the mRNA levels of the drug transporters. The impetus for upregulation in expression may also be
linked to the feeding and fasting behavior that is newly established after birth, as may be occurring with regulation of liver transporters (Eder and Ringseis; Kok et al., 2003). The fold-change increase in expression and function could also be attributed to morphological changes that are occurring in the maturing kidney. In humans, nephrogenesis is complete by 34 weeks of gestation, while in the rat nephrogenesis is complete between P7-P10 (Dickinson et al., 2005). Although the additional development of new nephrons could be responsible for the increases in transporter mRNA levels, it is more likely that the postnatal changes in segmental maturation of the individual S1, S2 and S3 segments of the proximal tubule could be a major contributing factor. In the rabbit, it is not until postnatal day 40 that all segments of the outer cortical tubules have reached maturity (Evan et al., 1983). Over this period of time all segments of the proximal tubule show increases in length with the S1 segment undergoing a 6-fold increase in segment length (Evan et al., 1983). In light of this, it should be considered that the formation of new nephron units and the extensive growth of established nephrons may also contribute to the high upregulation of Oat1 and Oat3 in the postnatal kidney.

In summary, this study provides a comprehensive overview of the maturation of drug transporter expression throughout the embryonic, postnatal, and maturation stages of renal development. Specific transporters are upregulated over the developmental time course which parallels the functional maturation observed in PAH clearance rates. It is vital that neonatal specific drug transport studies continue to be carried out if
pharmacological safety is to be enhanced and overdose or toxicity issues are to be avoided. Understanding how epithelial drug transporters, present at multiple interfaces (not only the blood-nephron barrier but also transepidermal, gut and blood-brain barrier), are regulated pre and postnatally is a key component to this endeavor, as well as understanding how intracellular drug metabolizing enzymes are working in concert with the transport mechanisms to detoxify or activate the pharmacological compounds. To this end, this study should serve a basis for investigations into the pharmacokinetics of neonatally relevant drugs transported by the renal drug transport system in the future.
ACKNOWLEDGEMENTS

We thank Shamara Closson and Jana Schroth for expert technical assistance and Megan Bettilyon for her editorial assistance.
AUTHORSHIP CONTRIBUTIONS

**Participated in research design:** Sweeney, Vallon, Rieg, Wu, and Nigam.

**Conducted experiment:** Sweeney, Vallon, Rieg, and Gallegos.

**Performed data analysis:** Sweeney, Vallon and Rieg.

**Wrote or contributed to the writing of the manuscript:** Sweeney, Vallon, Rieg, Wu, Gallegos and Nigam.

**Other:** Sweeney and Vallon contributed equally and should be considered as co-First Authors.
REFERENCES


Fleck C, Hilger R, Jurkutat S, Karge E, Merkel U, Schimske A and Schubert J (2002) Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF.


FOOTNOTES

Drs. Sweeney and Vallon contributed equally to this manuscript and should be considered co-First Authors. This work was supported by the National Institutes of Health National Heart, Lung and Blood Institute [Grant R01HL94728]; the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grants P30DK079337, DK079784]; the National Institutes of Health National Institute of Medical Sciences [Grant GM088824]; the Department of Veterans Affairs; the American Heart Association [Grant 10SDG2610034]; and the American Society of Nephrology Carl W. Gottschalk Research Scholar Grant.
FIGURE LEGENDS

Figure 1. Expression profile of SLC and ABC transporters during kidney development. A) Microarray expression profile of probe sets for the SLC family of transporters were plotted for each stage of kidney development. B) Expression profiles were also plotted for the ABC family of transporters. The x-axis represents the developmental stages of kidney development (Tsigelny et al., 2008).

Figure 2. The SLC22 family of transporters show overall increases in mRNA expression over the course of kidney development. A) The expression of Slc22 (Oat) transporters throughout kidney development highlights a number of transporters that show large increases in expression around the postnatal to mature stage. B) 2-fold filtering identifies the Slc22 genes which have a 2-fold change in expression between the consecutive stages of kidney development. The shaded cells highlight the stage comparison with the largest change in expression. Abbreviations: early emb, early embryonic stage; interm emb, intermediate embryonic; late emb, late embryonic stage. C) Specific expression of Slc22a6 (dashed line) and Slc22a8 (solid line) from e13 through to adulthood highlight maximal expression at adulthood.

Figure 3. Clinically relevant SLC and ABC transporters show increased expression throughout the stages of kidney development, with highest expression at the mature stage. A) The expression profiles for the SLC transporters and ABC transporters with
emerging clinical importance (Giacomini et al., 2010) were examined during kidney development. B) **Fold-change of expression in “clinically relevant” drug transporters.** 2-fold filtering identifies the clinically relevant drug transporters which have a 2-fold change in expression between the consecutive stages of kidney development. The shaded cells indicate the stage comparison with the largest fold change. Abbreviations: early emb, early embryonic stage; interm emb, intermediate embryonic; late emb, late embryonic stage.

**Figure 4.** *A number of clinically important drug transporters are specifically upregulated in the developing proximal tubule.* A) Using the GUDMAP consortium microarray datasets profiling the substructures of the developing mouse kidney, 2-fold filtering was carried out to identify which clinically relevant transporters are specifically upregulated in the developing proximal tubule. Six transporters show fold changes greater than 2-fold in the developing proximal tubule compared to other structures. For list of abbreviations of the GUDMAP substructures please refer to text. B) The average fold-change of transporters presented in B relative to the proximal tubule sample is tabulated. Average fold change is based on the geometric mean of fold change across all substructures.

**Figure 5.** *Age-dependent increase of PAH clearance in wild-type mice.* A) Elimination constant, volume of distribution and clearance of PAH were determined by plasma kinetics after i.v. bolus injection of PAH for mice at 1, 2 and 3 weeks of age. Data are
means ± SEM in 4-6 sets of mice per age (4-5 mice/set); results were similar for male and female and therefore were pooled. B) Plasma kinetics of PAH. C) Published data for PAH clearance derived from adult mice (8-10 weeks of age) (Eraly et al., 2006; Vallon et al., 2008) were included for comparison.

Figure 6. PAH clearance is attenuated at 2 weeks of age in Oat1−/− mice. A) The volume of distribution for PAH and inulin were similar between WT, Oat1−/− and Oat3−/− mice. B) Whereas body weight and the clearance of inulin were similar between genotypes, the clearance of PAH and the difference between PAH and inulin clearance (as an indirect measure of renal secretion) were significantly lower in Oat1−/− than in WT mice. C) Plasma kinetics of inulin and PAH in WT versus Oat1−/− mice. Data are means ± SEM in 6-7 sets of mice per genotype (5 mice/set); * P<0.05 vs. WT.
A. **Slc22 transporters**

B. **SLC22 transporters regulated at least 2 fold in at least 1 pair of between consecutive stages of kidney development**

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Title</th>
<th>Early embryonic</th>
<th>Intermediate embryonic</th>
<th>Late embryonic</th>
<th>Postnatal</th>
<th>Mature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slc22a2</td>
<td>Oct2</td>
<td>1.00</td>
<td>2.20</td>
<td>2.41</td>
<td>14.33</td>
<td></td>
</tr>
<tr>
<td>Slc22a12</td>
<td>Rst</td>
<td>1.51</td>
<td>1.84</td>
<td>5.53</td>
<td>7.98</td>
<td></td>
</tr>
<tr>
<td>Slc22a9</td>
<td>Oat5</td>
<td>1.30</td>
<td>2.50</td>
<td>0.92</td>
<td>6.20</td>
<td></td>
</tr>
<tr>
<td>Slc22a1</td>
<td>Oct1</td>
<td>0.92</td>
<td>2.10</td>
<td>3.67</td>
<td>4.78</td>
<td></td>
</tr>
<tr>
<td>Slc22a6</td>
<td>Oat1</td>
<td>2.14</td>
<td>3.84</td>
<td>1.70</td>
<td>4.59</td>
<td></td>
</tr>
<tr>
<td>Slc22a7</td>
<td>Oat2</td>
<td>0.98</td>
<td>1.01</td>
<td>1.32</td>
<td>4.35</td>
<td></td>
</tr>
<tr>
<td>Slc22a8</td>
<td>Oat3</td>
<td>1.53</td>
<td>3.63</td>
<td>3.80</td>
<td>3.44</td>
<td></td>
</tr>
<tr>
<td>Slc22a4</td>
<td>Octn1</td>
<td>1.21</td>
<td>1.08</td>
<td>2.94</td>
<td>3.43</td>
<td></td>
</tr>
<tr>
<td>Slc22a5</td>
<td>Octn2</td>
<td>1.16</td>
<td>1.37</td>
<td>4.07</td>
<td>2.87</td>
<td></td>
</tr>
</tbody>
</table>

C. **Slc22a6 and Slc22a8 transporters**

- Slc22a6
- Slc22a8
**A. Clinically relevant SLC and ABC transporters**

**B.**

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Title</th>
<th>Fold change between consecutive stages</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>([interm emb] vs [early emb])</td>
<td>([late emb] vs [interm emb])</td>
</tr>
<tr>
<td>Slc22a2</td>
<td>Oct2</td>
<td>1.00</td>
</tr>
<tr>
<td>Slc15a2</td>
<td>Pept2</td>
<td>2.56</td>
</tr>
<tr>
<td>Slc47a1</td>
<td>MATE1</td>
<td>3.23</td>
</tr>
<tr>
<td>Slc22a1</td>
<td>Oct1</td>
<td>0.92</td>
</tr>
<tr>
<td>Slc22a6</td>
<td>Oat1</td>
<td>2.14</td>
</tr>
<tr>
<td>Slc22a8</td>
<td>Oat3</td>
<td>1.53</td>
</tr>
<tr>
<td>Abcg2</td>
<td>Bcrp</td>
<td>1.33</td>
</tr>
<tr>
<td>Abcb1a</td>
<td>Mdr1a/P-gp</td>
<td>1.00</td>
</tr>
<tr>
<td>Abcc4</td>
<td>Mrp4</td>
<td>1.89</td>
</tr>
<tr>
<td>Abcc2</td>
<td>Mrp2</td>
<td>1.03</td>
</tr>
<tr>
<td>Abcb1b</td>
<td>Mdr1/Pgy1</td>
<td>0.96</td>
</tr>
</tbody>
</table>
**B.** List of clinically relevant transporters upregulated at least 2 fold in the proximal tubule compared to all other kidney structures

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>Gene Title</th>
<th>Average fold change across all components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slc47a1</td>
<td>Mate1</td>
<td>94.4</td>
</tr>
<tr>
<td>Slc22a2</td>
<td>Oct2</td>
<td>45.7</td>
</tr>
<tr>
<td>Slc22a1</td>
<td>Oct1</td>
<td>20.0</td>
</tr>
<tr>
<td>Slc15a2 *</td>
<td>Pept2</td>
<td>14.4</td>
</tr>
<tr>
<td>Slc22a6 *</td>
<td>Oat1</td>
<td>12.5</td>
</tr>
<tr>
<td>Slc22a8 *</td>
<td>Oat3</td>
<td>7.8</td>
</tr>
</tbody>
</table>

*Average of two probe sets
Figure 6

A

VD inulin (L/kg)  
VD PAH (L/kg)

WT  Oat3 -/-  Oat1 -/-

C

[Inulin] plasma (µg/L)

[PAH] plasma (µM)

WT  Oat1 -/-

time (min)

B

body weight (g)

inulin clearance (µL/min x g)

PAH clearance (µL/min x g)

(PAH - inulin) clearance (µL/min x g)

WT  Oat3 -/-  Oat1 -/-

*